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ABSTRACT 
 
Nanotechnology having developed exponentially, the aim has been on therapeutic undertaking, particularly for 
targetted drug therapy. In 1980 K. Eric Drexler developed and popularized the concept of nanotechnology. The 
nanocarriers has became a revolutionary approach. Nanocarriers are at forefront of the rapidly developing field of 
nanotechnology with several potential applications in drug delivery, clinical medicines and research. Nanostructure 
lipid carriers have attracted expanding scientific and commercial vigilance in the last couple of years as alternate 
carriers for the pharmaceutical consignment. A new generation of nanostructured lipid carriers (NLCs) consisting of 
a lipid matrix with a special nanostructured has been developed. This nanostructure improves drug loading and 
firmly incorporates the drug during storage. The present review gives insights on the definitions and characterization 
of NLC as colloidal carriers including the production techniques, stability techniques and suitable formulations. This 
review paper also highlights mechanism of skin penetration and the importance of NLC in pharmaceutical 
applications. 
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Introduction 
 
 
Since the beginning of 20th century, nanotechnology 
growing interest from the pharmaceutical technology 
research groups worldwide. It has practically made its 
influence in all technical fields. Industry estimates 
suggest that approximately 40% of lipophilic drug 
candidates fail due to solubility and formulation 
stability issues, which has been solved by various novel 
and advanced lipophilic drug delivery technologies [1]. 
The lipids employed to prepare lipid nanoparticles are 
usually physiological lipids (biocompatible and 
biodegradable) so, that drugs can be delivered at the 
required site of action with controlled release with low 
acute and chronic toxicity [2]. Nanotechnology is being 
applied extensively to provide targeted drug therapy, 
diagnostics, tissue regeneration, cell culture, biosensors 
and other tools in the field of molecular biology.To 
overcome the drawbacks associated to the traditional 
colloidal systems such as emulsions, liposomes and 
polymeric nanoparticles, various nanotechnology  
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platforms like Nanostructured Lipid Carrier, fullerenes, 
nanotubes, quantum dots, nanopores, dendrimers, 
liposomes, magnetic nanoprobes and radio controlled 
nanoparticles are being developed. 
 
NLC as compare to SLN 
Nanostructured lipid carrier (NLC), the second  
generation innovative lipid nanoparticle that acts as a 
bioactive carrier system, has been developed to 
overcome some potential limitations of the solid lipid 
nanoparticle (SLN). The review of Menhert and Mader 
highlight these apects: 
• Pay-load for number of drugs is too low. 
• Drug expulsion during storage. 
• High water content of SLN dispersion. 
To overcome drug expulsion during storage, use of 
lipid blends which do not form a highly ordered 
crystalline arrangement is needed. The matrix of NLCs 
is composed of mixture of spatially different lipid 
molecules, normally mixture of solid and liquid lipid, 
which makes more imperfection in the matrix to 
accommodate more drug molecules than SLN. Despite 
the presence of liquid lipid, NLC matrix is solid at 
room/body temperature. NLCs adopt mixtures of a 
solid lipid and liquid lipid and remain in the solid state 
by controlling the content of liquid lipid. NLCs can 
more strongly immobilize drugs and prevent the 
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particle from coalescing by virtue of the solid matrix 
compared to emulsions.NLC has attracted increasing 
scientific and commercial attention during the last few 
years [3,4] due to the lower risk of systemic side 
effects.In addition, the expulsion of drug entrapped in 
NLC during storage is minimized or avoided. NLC is 
an alternative carrier to other drug carrier systems such 
as liposomes and polymeric nanoparticles because it 
has combined the advantages of other colloidal carriers 
and avoided their disadvantages. These includes high 
amounts of drug payload, increasing drug stability, the 
possibility to control drug release and targeting, and 
avoidance of organic solvents [5]. 
 
 
Figure1: Triggered release of drug from NLC the transform form of SLN 
 
NLCs are composed of biocompatible solid lipid 
matrices and liquid lipid which have different chemical 
structure from the solid lipid [6]. Besides, NLCs have 
the usual particle diameter ranging 10–1000 
nm.Nanostructured lipid carriers (NLC) are the second 
generation SLN composed of solid lipid matrix which 
are incorporated with liquid lipids [7]. Among the 
nanostructured lipid carriers that contain solid lipids 
together with liquid oils are, Miglyol®, α-tocopherol, 
etc [8]. The presence of liquid lipids with different 
fatty acid C-chains produces NLC with less organized 
crystalline structure and therefore provides better 
loading capacity for drug accommodation [9]. Liquid 
lipids are better solubilizers of drugs than solid 
lipids.These carriers are composed of physiological and 
biodegradable lipids exhibiting low systemic toxicity 
and low cytotoxicity[10]. Most of the used lipids have 
an approved status or are excipients used in 
commercially available pharmaceutical preparations. 
The small size of the lipid particles ensures close 
contact to stratum corneum and can increase the 
amount of drug penetrating into mucosa or skin. Due to 
their solid lipid matrix, a controlled release from these 
carriers is possible. This becomes an important tool 
when it is necessary to supply the drug over prolonged 
period of time, to reduce systemic absorption, and 
when drug produces irritation in high concentrations 
[11,12,13]. NLC have been shown to exhibit a 
controlled release behavior for various active 
ingredients such as ascorbyl palmitate, 
clotrimazole,ketoconazole, and other antifungal agents. 
 
Advantages of NLCs 
• Better physical stability, 
• Ease of preparation and scale-up, 
• Increased dispersability in an aqueous 
medium, 
• High entrapment of lipophilic drugs and 
hydrophilicdrugs, 
• Controlled particle size, 
• An advanced and efficient carrier system in 
particular forsubstances, 
• Increase of skin occlusion, 
• Extended release of the drug, 
• One of the carriers of choice for topically 
applied drugs because their lipid components 
have an approved status or are excipients used 
in commercially available topical cosmetic or 
pharmaceutical preparations, 
• Small size of the lipid particles ensures close 
contact to the stratum corneum thus enhancing 
drug penetration into the mucosa or skin, 
•  Improve benefit/risk ratio, 
•  Increase of skin hydration and elasticity  and 
• These carriers are highly efficient systems due 
to their solid lipid matrices, which are also 
generally recognized as safe or have a 
regulatory accepted status [14]. 
 
Limitation of NLCs 
 
Despite the great potential of NLCs in targeted 
delivery, theyface certain limitations like: 
• Cytotoxic effects related to the nature of 
matrix and concentration, 
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•  Irritative and sensitising action of some 
surfactants, 
•  Application and efficiency in case of protein 
and peptide drugs and gene delivery systems 
still need to be better exploited, and 
• Lack of sufficient preclinical and clinical 
studies with these nanoparticles in case of 
bone repair [15]. 
 
Types of NLC 
Different methods have been proposed for creating 
NLCs: 
I. Imperfect type NLC (imperfectly structured 
solid matrix): Spatially different lipids are 
mixed, and thus imperfections in the crystal 
order of lipid nanoparticles are provided. 
Large distances between fatty acid chains in 
the matrix structure of lipid nanoparticles can 
be increased by using glycerides composed of 
very different fatty acids. Therefore, the 
matrix contains imperfections to 
accommodate the drug in amorphous clusters 
(Figure1. upper). Mixing small amounts of 
chemically very different liquid lipids (oils) 
with solid lipids in order to achieve the 
highest incompatibility leads the highest drug 
payload. 
II. Amorphous type (structureless solid 
amorphous matrix): This kind of NLC can be 
achieved by mixing solid lipids with special 
lipids, eg, hydroxy octa 
cosanylhydroxystearate, isopropylmyristate or 
medium chain triglycerides such as 
Miglyol® 812. Therefore, drug expulsion 
caused by the process of crystallization to β 
forms during storage is prevented by the 
special structure of the lipid matrix since NLC 
are solids in an amorphous but not crystalline 
state [Figure 1.middle] [16]. 
III. Multiple type (multiple oil in fat in water 
(O/F/W) carrier): The solubility of the drug in 
the lipophilic phase decreases during the 
cooling process after homogenization and the 
crystallization process during storage. 
Continuously reducing drug solubility leads to 
drug expulsion from the lipid nanoparticles 
especially when the drug concentration in the 
formulation is too high. Solubility of many 
drugs in a liquid lipid is higher than in a solid 
lipid. When lipids lack appropriate drug 
solubilities, addition of a higher amount of 
liquid lipid to the lipophilic phase displays the 
advantages of the solid matrix which 
prevented drug leakage while the liquid 
regions (oily nanocompartments) show 
comparatively high solubility for lipophilic 
drugs [Figure  1. Lower] [17]. 
 
Figure: 2Types of NLC: (I) imperfect type, (II) amorphous type and (III) multiple type 
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Ingredients used in the formulation of Nano  
structured lipid carrier drug delivery systems 
 
The essential ingredients for NLCs include lipids, 
water, and emulsifiers. 
 
Emulsifiers 
 
The emulsifiers have been used to stabilize the lipid 
dispersions. Most of the investigations employ 
hydrophilic emulsifiers such as Pluronic F68 
(poloxamer 188), polysorbates (Tween), polyvinyl 
alcohol, and sodium deoxycholate[18-20]. Lipophilic 
or amphiphilic emulsifiers such as Span 80 and lecithin 
are employed for fabrication ofNLCs if necessary. It 
has been found that the combination of emulsifiers can 
prevent particle aggregation more efficiently[21]. 
Polyethylene glycol (PEG), sometimes added in NLCs, 
resides on the nanoparticulate shell to prevent uptake 
by the reticuloendothelial system (RES) and to prolong 
the circulation time of drugs. Table 1 summarizes the 
detailed information pertaining to the materials used 
for NLCs. Another prerequisite for NLCs’ stability is 
the ability for preservation. The preservatives can 
impair the physical stability of lipid dispersions. 
Obeidat et al.[22] demonstrate that Hydrolite® 5 is 
proved suitable for the preservation of coenzyme Q10-
loaded NLCs 
Table 1: The excipients for composing nanostructured lipid carriers (NLCs) 
 
Ingredient Material 
Solid lipids Tristearin, stearic acid, cetyl palmitate, cholesterol, Precirol® ATO 5, Compritol® 
888 ATO, Dynasan®116, Dynasan® 118, Softisan® 154, Cutina® CP, Imwitor® 900 
P, Geleol®, Gelot® 64, Emulcire® 61 
Liquid lipids Medium chain triglycerides, paraffin oil, 2-octyl dodecanol, oleic acid, squalene, 
isopropyl myristate,vitamin E, Miglyol® 812, Transcutol® HP, Labrafil Lipofile® 
WL 1349, Labrafac® PG, Lauroglycol® FCC,Capryol® 90 
Hydrophilic emulsifier Pluronic® F68 (poloxamer 188), Pluronic® F127 (poloxamer 407), Tween 20, Tween 
40, Tween 80,polyvinyl alcohol, Solutol® HS15, trehalose, sodium deoxycholate, 
sodium glycocholate, sodium oleate,polyglycerol methyl glucose distearate 
Lipophilic emulsifiers Myverol® 18-04K, Span 20, Span 40, Span 60 
Amphiphilic emulsifiers Egg lecithin, soya lecithin, phosphatidylcholines, phosphatidylethanolamines, 
Gelucire® 50/13 
 
Lipids 
 
Both solid and liquid lipids are included in NLCs for 
constructing the inner cores. The solid lipids 
commonly used for NLCs include glyceryl behenate 
(Com- pritol® 888 ATO), glyceryl palmitostearate 
(Precirol® ATO 5), fatty acids (e.g. stearic acid), 
triglycerides (e.g. tristearin), steroids (e.g. cholesterol), 
and waxes (e.g. cetyl palmitate). These lipids are in a 
solid state at room temperature. They would melt at 
higher temperatures (e.g. > 80°C) during the 
preparation process. Liquid oils typically used for 
NLCs consist of digestible oils from natural sources. 
The medium chain triglycerides, such as Miglyol® 
812, are often utilized as the constituents of liquid 
lipids because of their similar structures to Compritol® 
[23]. Other oily components such as paraffin oil, 2-
octyl dodecanol, propylene glycol dicaprylocaprate 
(Labrafac®), isopropyl myristate and squalene are 
included as well. Alternatively, the fatty acids, such as 
oleic acid, linoleic acid, and decanoic acid, are 
included in NLCs for their value as having oily 
components and as being penetration enhancers of 
topical delivery. In general, these lipids are already 
approved by European and American regulatory 
authorities for clinical applications and for their 
“generally recognized as safe” (GRAS) status. There is 
a need for novel and biocompatible oils that are cost-
effective, non-irritating, and capable of being sterilized 
before application. Vitamin E (α-tocopherol) and other 
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tocols have been investigated as materials for 
nanoemulsions [24]. Tocols can serve as a choice of 
oils for NLCs because of their stability, ease of 
production on a large scale, and good solubility in 
lipophilic drugs. NLCs produced using natural oils 
from plants are also currently popular. Averina et al. 
[25,26] have used Siberian pine seed oil and fish oil 
from Baikal Lake as the liquid oils since they show 
acceptable physical and chemical stability to NLCs. 
 
Preparation procedures of nanostructured lipid 
carriers (NLCs) 
 
There many methods for the preparation of lipid 
nanoparticulate DDS. The method used is dictated by 
the type of drug especially its solubility and stability, 
the lipid matrix, route of administration, etc. 
 
High Pressure Homogenization Technique 
HPH has been used as a reliable and powerful 
technique for the large-scale production of NLCs, lipid 
drug conjugate, SLNs, and parenteral emulsions. In 
High Pressure Homogenization technique lipid are 
pushed with high pressure (100-200bars) through a 
narrow gap of few micron ranges. So shear stress and 
cavitation are the forces which cause the disruption of 
particle to submicron range.  Normally the lipid 
contents are in the range of 5-10%. In contrast to other 
preparation technique High Pressure Homogenization 
does not show scaling up problem.Basically there are 
two approaches for production by high pressure 
homogenization, hot and cold homogenization 
techniques [27]. For both the techniques drug is 
dissolved in the lipid being melted at approximately 5-
10º C above the melting point. 
 
Hot Homogenization Technique 
In this technique the drug along with melted lipid is 
dispersedunder constant stirring by a high shear device 
in the aqueous surfactant solution of same temperature. 
The pre-emulsion obtained is homogenised by using a 
piston gap homogeniser and the obtained nanoemulsion 
is cooled down to room temperature where the lipid 
recrystallises and leads to formation of nanoparticles 
[28]. 
 
Cold homogenisation technique 
Cold homogenisation is carried out with the solid lipid 
containing drug. Cold homogenisation has been 
developed to overcome the problems of the hot 
homogenisation technique such as, temperature 
mediated accelerated degradation of the drug payload, 
partitioning and hence loss of drug into the aqueous 
phase during homogenisation. The first step of both the 
cold and hot homogenisation methods is the same. In 
the subsequent step, the melt containing drug is cooled 
rapidly using ice or liquid nitrogen for distribution of 
drug in the lipid matrix as shown in the Figure 2. Cold 
homogenisation minimises the thermal exposure of the 
sample [29]. 
 
 
 
Figure 3: Schematic overview of the hot and cold homogenisation technique 
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Microemulsion technique 
The lipids (fatty acids or glycosides eg. Stearic acid) 
are melted and drug is incorporated in molten lipid.A 
mixture of water, co-surfactant(s) and the surfactant is 
heated to the same temperature as the lipids and added 
under mild stirring to the lipid melt. A transparent, 
thermodynamically stable system is formed when the 
compounds are mixed in the correct ratios for 
microemulsion formation. Thus the microemulsion is 
the basis for the formation of nanoparticles of a 
requisite size.This microemulsion is then dispersed in a 
cold aqueous medium under mild mechanical mixing 
of hot microemulsion with water in a ratio in the range 
1:25 – 1:50. This dispersion in cold aqueous medium 
leads to rapid recrystallisation of the oil droplets. [30]. 
 
Solvent emulsification-evaporation technique  
In solvent emulsification-evaporation technique, the 
hydrophobic drug and lipophilic material were 
dissolved in a water immiscible organic solvent (e.g. 
cyclohexane, dichloromethane, toluene, chloroform) 
and then that is emulsified in an aqueous phase using 
high speed homogenizer. To improve the efficiency of 
fine emulsification, the coarse emulsion was 
immediately passed through the microfluidizer. 
Thereafter, the organic solvent was evaporated by 
mechanical stirring at room temperature and reduced 
pressure (e.g. rotary evaporator) leaving lipid 
precipitates of SLNs. Here the mean particle size 
depends on the concentration of lipid in organic phase. 
Very small particle size could be obtained with low 
lipid load (5%) related to organic solvent. The big 
advantage of this method is the avoidance of any 
thermal stress, which makes it appropriate for the 
incorporation of highly thermolabile drugs. A clear 
disadvantage is the use of organic solvent which may 
interact with drug molecules and limited the solubility 
of the lipid in the organic solvent [31]. 
 
Solvent emulsification-diffusion technique 
In solvent emulsification-diffusion technique, the 
solvent used (e.g. benzyl alcohol, butyl lactate, ethyl 
acetate, isopropyl acetate, methyl acetate) must be 
partially miscible with water and this technique can be 
carried out either in aqueous phase or in oil. Initially, 
both the solvent and water were mutually saturated in 
order to ensure the initial thermodynamic equilibrium 
of both liquid. When heating is required to solubilize 
the lipid, the saturation step was performed at that 
temperature. Then the lipid and drug were dissolved in 
water saturated solvent and this organic phase (internal 
phase) was emulsified with solvent saturated aqueous 
solution containing stabilizer (dispersed phase) using 
mechanical stirrer. After the formation of o/w 
emulsion, water (dilution medium) in typical ratio 
ranges from 1:5 to 1:10, were added to the system in 
order to allow solvent diffusion into the continuous 
phase, thus forming aggregation of the lipid in the 
nanoparticles. Here the both the phase were maintain at 
same elevated temperature and the diffusion step was 
performed either at room temperature or at the 
temperature under which the lipid was dissolved. 
Throughout the process constant stirring was 
maintained. Finally, the diffused solvent was 
eliminated by vacuum distillation or lyophilization[32]. 
 
Phase inversion temperature (PIT) method 
Phase inversion of O/W to W/O emulsions and vice 
versa induced by temperature change is a long known 
method to produce microemulsions stabilized with 
non-ionic surfactants [94]. The technique is based on 
the change in the properties of polyoxyethylated 
surfactants at different temperatures. The hydrophillic-
lipophillic balance (HLB) value of surfactants defined 
by Griffin is valid at 25°C. At this temperature the 
hydrophilic parts of the SAC molecules are hydrated to 
a certain extent. An increase in the temperature causes 
dehydration of the ethoxy groups. As a result, the 
lipophilicity of the molecules of the SAC rises with 
corresponding decrease in HLB value.At a certain 
point the affinity of the SAC to the aqueous and lipid 
phase is equal - this temperature is defined as the phase 
inversion temperature. This particulate state is 
characterized by very lowsurface tension and presence 
of complex structures in the system. If the temperature 
is further increased the SAC’s affinity to the lipid 
phase becomes higher enough to stabilize emulsions of 
w/o type. 
 
Melting dispersion method 
In melting method, drug and solid lipid are melted in 
an organic solvent regarded as oil phase, and 
simultaneously water phase is also heated to the same 
temperature as oil phase. Subsequently, the oil phase is 
added to a small volume of water phase and the 
resulting emulsion is stirred at high speed for few 
hours. Finally, it is cooled down to room temperature 
to yield nanoparticles [33]. 
 
High Shear Homogenization or Ultrasonication 
Technique 
Ultrasonication based on the mechanism ofcavitation. 
In first step, the drug was added to previously melt 
solid lipid. In second step, the heated aqueous phase 
(heated to same temperature) was added to the melted 
lipid and emulsified by probe sonication or by using 
high speed stirrer or aqueous phase added to lipid 
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phase drop bydrop followed by magnetic stirring. The 
obtained pre-emulsion was ultrasonicated usingprobe 
sonicator with water bath (at 0ºC). In order to prevent 
recrystalization during the process,the production 
temperature kept at least 5ºC above the lipid melting 
point. The obtained product was filtered through a 
0.45µm membrane in order to remove impuritiescarried 
in during ultrasonication [34]. 
 
Solvent injection (or solvent displacement)technique  
Technique in which a solvent that distributes very 
rapidly in water (DMSO, ethanol) is used [35]. First the 
lipid is dissolved in the solvent and then it is quickly 
injected into an aqueous solution of surfactants through 
an injection needle. The solvent migrates rapidly in the 
water and lipid particles precipitate in the aqueous 
solution.As shown in Figure 6 schematic overview of 
Solvent injection method. Particle size depends on the 
velocity of distribution processes. Higher velocity 
results in smallerparticles. The more lipophilic solvents 
give larger particles which may become an issue. The 
method offers advantages such as low temperatures, 
low shear stress, easy handling and fast production 
process without technically sophisticated equipment 
(e.g. high-pressure homogeniser). However, the main 
disadvantage is the use of organic solvents. 
 
Figure 4: Schematic representation of solvent injection method 
 
Double emulsion technique 
In double emulsion technique the drug (mainly 
hydrophilic drugs) is dissolved in aqueous solution, 
and further emulsified in melted lipid. The primary 
emulsion is stabilised by adding stabiliser that is 
dispersed in aqueous phase containing hydrophilic 
emulsifier, which is followed by stirring and filtration. 
Double emulsion technique avoids the necessity to melt 
the lipid for the preparation of peptide-loaded lipid 
nanoparticles and the surface of the nanoparticles could 
be modified in order to sterically stabilise them by 
means of the incorporation of lipid-PEG derivatives 
[36].Various factors require for successful formulation 
as shown inFigure 5 Parameters in producing a 
successful lipid nanoparticle formulation 
 
 
Figure 5: Parameters in producing a successful lipid nanoparticle formulation 
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Strategies employed for overcoming the issues related  
to stability of NLCs 
 
Spray drying 
Spray drying It is an alternative and cheaper technique 
to the lyophilization process. This recommends the use 
of lipid with melting point more than 70ºC. The best 
results were obtained with SLN concentration of 1% in 
a solution of trehalose in water or 20% trehalose in 
ethanol-water mixture. The addition of carbohydrates 
and low lipid content favor the preservation of the 
colloidal particle size in spray drying. The melting of 
the lipid can be minimized by using ethanol–water 
mixtures instead of pure water due to cooling leads to 
small and heterogeneous crystals, the lower inlet 
temperatures. 
 
Lyophilisation 
Lyophilization is a promising way to increase the 
chemical and physical stability over extended periods 
of time. Lyophilization had been required to achieve 
long term stability for a product containing 
hydrolysable drugs or a suitable product for per -oral 
administration. Transformation into the solid state 
would prevent the Oswald ripening and avoid 
hydrolytic reactions.However, when SLN are 
lyophilised without cryoprotectant, the final product 
commonly results in the aggregation of particles. Some 
of the most widely used cryoprotectants are trehalose, 
sorbitol, glucose, sucrose, mannose and maltose. 
Schwarz and Mehnert reported trehalose as the most 
effective cryoprotectant in preventing particle growth 
[37]. 
 
Stabilizing agent 
a. Poloxamers 
• Poloxamer 188 used in a formulation that was 
developed and then in human plasma and 
whole blood showed that showed an increased 
whole blood permeability of networks and it 
was also observed that the increased fibrin 
permeability was due to fibrin fibres 
arrangement. The alterations of fibrin are the 
main reason to increase the mechanical 
stability contributing to antithrombotic and 
rheological effects [38,39].  
• There was also increase in stability of the gel 
formulation using Poloxamer with organic 
solvents such as ethanol, propylene glycol, 
glycerol and PEG 400. Poloxamer 407 in the 
presence of these organic solvents, self 
assembles into two liquid crystal structures 
namely micellar cubic and hexagonal 
structures that are thermodynamically stable.  
• Poloxamer 407 in combination with a 
liposome showed an increase in stability of 
liposome formulation by increasing half life, 
preventing aggregation and fusion of 
phosphatidylcholine multilamellar 
vesicles[40]. The low stability of poloxamer 
hydrogel in an aqueous solution lead to the 
combination development of poloxamer 407 
with acrylate and thiol groups of 17.5 wt % at 
body temperature. It was observed with an 
immediate crosslinking formed between 
acrylate and thiol that modified poloxamer 
407 property, giving rise to a remarkable 
increase in stability of drugs about four times 
and for its potential application in controlled 
drug release [41]. 
b. Polyethylene glycol 
lIn general, surface modification of colloidal 
particles by coating with a hydrophilic 
substance like polyethylene glycol(PEG) 
reported to bring following benefits: 
• Providing good physical stability 
and dispersability of colloids 
• Improving presence of colloids in 
blood circulation for systemic use 
• Increasing stability of colloids in 
body fluids such as gastrointestinal 
(GI) fluids, 
• Acceleration of colloid transport 
across the epithelium, 
• Modulation of interaction of colloids 
with mucosa for specific delivery 
requirements and drug targeting, 
• Increasing biocompatibility and 
decreasing thrombogenicity of drug 
carriers. 
Mechanism of skin penetration of NLCs 
Nanosized particles can make close contact with 
superficial junctions of SC and furrows between 
corneocyte islands, allowing superficial spreading of 
the active agents. Following the evaporation of water 
from the nanosystems applied to the skin surface, 
particles form an adhesive layer occluding theskin. 
Hydration of SC thus increases to reduce corneocyte 
packing and widen inter-corneocyte gaps. Hydration 
also influences partitioning of the drug into SC[42]. 
Intact nanoparticles sized above 100 nm are not 
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considered to permeate the SC because of their 
dimensions and rigidity [43].Although the particles do 
not penetrate across SC, uptake ofthe components is to 
be expected. Since epidermal lipids arerich in SC, lipid 
nanoparticles attaching to the skin surface would allow 
lipid exchange between SC and the nanocarriers[44]. 
Lipid nanoparticles have the potential to deliver 
drugsvia the follicles [45]. Furthermore, each follicle is 
associatedwith sebaceous glands, which release sebum, 
creating anenvironment enriched in lipids [46]. This 
environment isbeneficial for trapping of lipid 
nanoparticles. Sebum is amixture of triglycerides, 
squalene and waxes. Some glyceridelipids present in 
NLCs may accelerate the entrance intothe 
follicles/sebaceous glands. The possible 
mechanismsinvolved in skin permeation enhancement 
by NLCs are depictedin Fig. [6]. 
  
Close contact to skin surface.skin hydration by particle occlusion 
 
 
Lipid exchange between SC and NLCsEntrance into follicles and sebaceous glands 
 
Figure 6:  Possible mechanisms for skin permeation enhancement of drugs or active ingredients from 
Nanostructure lipid carriers (NLCs) 
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Applications of NLCs 
 
Oral drug delivery 
Interest in NLCs for oral administration of drugs has 
been increasing in recent years. Increased 
bioavailability and prolonged plasma levels are 
described for peroral administration of NLCs. The lipid 
nanocarriers can protect the drugs from the harsh 
environment of the gastrointestinal tract. The lipophilic 
drugs can be entrapped by NLCs to resolve insolubility 
concerns. Repaglinide, an anti-diabetic agent with poor 
water solubility, has low oral bioavailability and a short 
halflife [47]. It is suitable to load into NLCs for 
improving oral delivery. Date et al. [48] prepare 
repaglinide NLCs with Gelucire 50/13 as an 
amphiphilic lipid excipient. Gelucire 50/13(stearoyl 
macrogolglycerides) has been previously used for the 
preparation of solid dispersions for improving the 
aqueous solubility of lipophilic drugs [49]. DSC 
studies indicate that Gelucire 50/13 interacts with 
Precirol® and that this interaction suppresses 
polymorphic transitions of both components. The 
NLCs exhibit a significantly greater decrease of the 
blood glucose level (about 2-fold) in rats compared to 
marketed repaglinide tablets The chemotherapeutic 
agent etoposide is used as a model drug. Etoposide is a 
poorly water-soluble drug and a substrate of P-
glycoprotein with a considerable intra- and inter-
patient variation of oral bioavailability. PEG or 
distearoylphosphatidylethanolamine- PEG (DSPE-
PEG) is added into NLCs as a stabilizer to increase 
circulation time. The absorption of etoposide in the 
intestine is evaluated by an in vitro diffusion chamber. 
The formulations with smaller size are easier to 
penetrate across the intestine wall. A pharmacokinetic 
study is conducted in rats. After oral administration at a 
drug dose of 180 mg/kg, the relative bioavailability 
etoposide from standard NLCs, PEG-containing NLCs, 
and DSPE-PEG-containing NLCs is enhanced 1.8-, 
3.0- and 3.5-fold, respectively, compared with control 
dispersion. DSPE-PEG-containing NLCs display the 
highest cytotoxicity against lung carcinoma cells 
among all carriers tested. 
 
Drug delivery to brain 
 Brain targeting not only increases the cerebrospinal 
fluid concentration of the drug but also reduces the 
frequency of dosing and side effects. The major 
advantages of this administration route are avoidance 
of first pass metabolism and rapid onset of action as 
compared to oral administration. LNC (e.g. NLC) of 
this generation are considered to be one of the major 
strategies for drug delivery without any modification to 
the drug molecule because of their rapid 
uptake by the brain, bioacceptability and 
biodegradability. Further, the feasibility in scale-up and 
absence of burst effect make them more promising 
carriers for drug delivery. In addition, NLC further 
enhanced the intranasal drug delivery of duloxetine in 
the brain for the treatment of major depressive 
disorder. Nanostructured Lipid Carriers (NLCs) of 
Asenapine maleate to improve the bioavailability and 
enhance the uptake of ASN to the brain[50]. In 
Bromocriptine loaded NLCs the In‐vivo results showed 
bromocriptine NLCs have rapid onset of action and 
longer duration and higher brain levels as compared to 
that of solution, entrapment efficiency was also 
increased [51]. 
 
Topical drug delivery 
Tacrolimus – loaded NLCs were successful 
prepared.The penetration rate of these NLCs through 
the skin of a hairless mouse was greater than that of 
Prototopic®. In vitro penetration tests revealed that the 
tacrolimus-loaded NLCs have a penetration rate that is 
1.64 times that of the commercial tacrolimus ointment, 
Protopic®[52].An increase of skin penetration was 
reported forcoenzyme Q 10 (Q10)-loaded SLN 
compared toQ10 in liquid paraffin and isopropanol. 
Thecumulative amounts of Q10 were 
determinedperforming a tape stripping test. After five 
stripsthe cumulative amount of Q10 was 1%, 28%and 
53% of the applied amount from the liquidparaffin, the 
isopropanol and the SLNformulation, respectively. 
Similar results wereachieved by another study for Q10-
loaded NLC. 
 
Pulmonary drug delivery 
Inhalation drug delivery represents a potential delivery 
route for the treatment of several pulmonary disorders. 
NLCs have greater stability against the shear forces 
generated during nebulization compared to polymeric 
nanoparticles, liposomes and emulsions.NLCs are 
comprised of an inner oil core surrounded by an outer 
solid shell and hence allow the high payload of a 
lipophilic drug8. NLCs in pulmonary disorders seems 
to be promising strategy (discussed in table 2) since 
lung epithelium can be directly reached resulting in 
faster onset of action, desired dose and dosing 
frequency can be reduced as compared to other 
administered routes like oral and undesirable side 
effects of drugs can be avoided. Bioadhesive properties 
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of NLCs are due to their smallparticle size as well 
lipophilic character lead to longerresidence time in 
lungs[53,54]. 
 
Cancer Chemotherapy 
 In supplement, the function of NLC in cancer 
chemotherapy is presented and hotspots in research are 
emphasized. It is foreseen that, in the beside future, 
nanostructured lipid carriers will be further advanced to 
consign cytotoxic anticancer compounds in a more 
efficient, exact and protected manner. ZER into NLC 
did not compromise the anti-proliferative effect of 
ZER. Both ZER and ZER-NLC significantly induced 
apoptosis via the intrinsic pathway in time-dependent 
manner. The proposed mechanism of apoptosis of 
cancer cells induced by ZER and ZER-NLC is via 
activation of caspase-9 and caspase-3, inhibition of 
anti-apoptotic protein, and stimulation of proapoptotic 
protein expressions. Loading of ZER into NLC will 
increase the bioavailability of the insoluble ZER in the 
treatment of cancers [55].g l-arginine lauril ester (AL) 
into nanostructure lipid carriers (NLCs) and then 
coating with bovine serum albumin(BSA),pH-sensitive 
membranolytic and lysosomolyticnanocarriers (BSA-
AL-NLCs) were developed to improve the anti-cancer 
effect y render more nanocarriers lysosomolytic 
capability with lower cytotoxicity, as well as improved 
therapeutic index of loaded active agents[56]. 
 
Parasitic treatment 
Novel colloidal delivery systems have gained 
considerable interest for anti‐parasitic agents with 
focus on 3 major parasitic diseases viz. malaria, 
leishmaniasis and trypanosomiasis. Lipid Nanoparticles 
combine advantages of traditional colloidal drug carrier 
systems like liposomes,polymeric nanoparticles and 
emulsions but at the same time avoid or minimize the 
drawbacks associated with them. The delivery system 
should be designed in such a way that 
physico‐chemical properties and pharmacokinetic 
properties are modulated of the anti‐parasitic agents 
(formulated as NLCs shown in table 5) in order to 
improve biospecificity (targetablity) rather than 
bioavailability with minimization in the adverse effects 
associated with it. SLNs and NLCs have ability to 
deliver hydrophobic and hydrophilic drug with more 
physical and biocompatibility Dihydroartemisnin 
(Anti-malarial) loaded NLCs The drug release 
behaviour from the NLC exhibited a biphasic pattern 
with burst release at the initial stage and sustained 
release subsequently [57]. 
 
 
 
Ocular delivery 
The characteristic features of SLNs and NLCs for 
ocular application are the improved local tolerance and 
less astringent regulatory requirements due to the use 
of physiologically acceptable lipids. The other benefits 
include the ability to entrap lipophilic drugs, protection 
of labile compounds, and modulation of release 
behaviour[58]. SLNs have been used for ocular drug 
delivery in the last decades. Recently, further 
investigations employing NLCs as ocular delivery 
systems have become knownIn Cyclosporine loaded 
NLCs the mucoadhesive properties of the thiolated 
non‐ionic surfactant Cysteine polyethylene glycol 
stearate (Cys‐  PEG‐SA) and NLC modified by this 
thiolated agent were evaluated. Cys‐PEG‐SA and its 
resultant NLC provided a promising system with 
prolonged residence time [59]. Lutein- loaded NLCs 
could protect the entrapped lutein in the presence of 
simulated gastric fluid and slowly released lutein in 
simulated intestinal fluid in an in‐vitro 
study[60].Triamcinoloe acetonide (TA)- loaded NLCs 
increased ocular absorption and enhanced prolonged 
drug residence time in the ocular surface and 
conjunctival sac, by sustained drug release from the 
delivery system, it also reduced precorneal drug loss 
[61]. 
 
Intranasal drug delivery 
The use of nanocarriers provides suitable way for the 
nasal delivery of antigenic molecules.These represent 
the key factors in the optimal processing and 
presentation of the antigen. Nasal administration is the 
promising alternative noninvasive route of drug 
administration due to fast absorption and rapid onset of 
action, avoiding degradation of labile drugs (peptides 
and proteins)  in the GI tract and insufficient transport 
across epithelial cell layers. The development of a 
stable nanostructured lipid carrier (NLC) system as a 
carrier for curcumin (CRM) biodistribution studies 
showed higher drug concentration in brain after 
intranasal administration of NLCs than PDS. The 
results of the study also suggest that CRM-NLC is a 
promising drug delivery system for brain cancer 
therapy [62].In addition, NLC further enhanced the 
intranasal drug delivery of duloxetine in the brain for 
the treatment of major depressive disorder. 
Nanostructured Lipid Carriers (NLCs) of Asenapine 
maleate to improve the bioavailability and enhance the 
uptake of ASN to the brain[50]. 
 
Parentral drug delivery  
The nano-drug delivery systems such as nanomicelles, 
nanoemulsions and nanoparticles has displayed a great 
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potential in improved parenteral delivery of the 
hydrophobic agents since last two decades. NLC has 
been considered as an alternative to liposomes and 
emulsions due to improved properties such as ease in 
manufacturing, high drug loading, increased flexibility 
in modulating drug release profile, and alongwith 
these, their aqueous nature and biocompatibility of the 
excipients has enabled intravenous delivery of the drug 
with passive targetingability and easy 
abolishment.Another reported example is NLCs of 
artemether (Nanoject) that offers significant 
improvement in the anti-malarial activity and duration 
of action as compared to the conventional injectable 
formulation. Nanoject can be considered asa viable 
alternative to the current injectable intramuscular(IM) 
formulation [63,64].Bufadienolides a class C-24 steroid 
also proved to be effectivein terms of enhanced 
haemolytic activity and cytotoxicitywith reduced side 
effects when incorporated in NLCs[65]. 
Nanostructured lipid carriers (NLCs) were prepared 
and optimized for the intravenous delivery of β-
Elemene (β-E)  β-E-NLCs showed a significantly 
higher bioavailability and anti-tumor efficacy than 
Elemene injection. β-E-NLCs described in this study 
are well-suited for the intravenous delivery of β-E[66]. 
 
Cardiovascular treatment 
Lipid nanoparticles as a carrier system has superiorities 
mainly prolonged circulation time and increased area 
under the curve (AUC) with manageable burst effect. 
NLCs would provide highly desirable physic‐chemical 
characteristics as a delivery vehicle for lipophilic 
drugs. Drug loading and stability were improved. 
Tashinone (TA) loaded NLCs the in‐vitro incubation 
tests confirmed that TA‐NLC could bind to apoA‐I 
specifically. Macrophage studies demonstrated that 
TA‐NLC incubated with native HDL could turn 
endogenous by association to apo‐lipoproteins, which 
cannot trigger immunological responses and could 
escape from recognition by macrophages 
[67].Nifedipine loaded NLCs Nanoparticle suspensions 
were formulated with negatively charged phospholipid, 
dipalmitoyl phosphatidylglycerol in preventing 
coagulation to improve solubility and hence 
bioavailability of drug [68]. In Lovastatin loaded NLCs 
, NLCs were developed to promote oral absorption of 
lovastatin. More than 70% lovastatin was entrapped in 
the NLCs. The in‐vitro release kinetics demonstrated 
that lovastatin release could be reduced by up to 60% 
with lipid nanoparticles containing Myverol as the 
lipophilic emulsifier. NLCs showing the slowest 
delivery. The oral lovastatin bioavailability was 
enhanced from 4% to 24% and 13% when the drug was 
administered from NLCs containing Myverol and SPC 
as surfactants respectively [69]. 
 
Cosmetic Applications of NLC 
Lipid nanoparticles—SLN and NLC—can be used to 
formulate active compounds in cosmetics, e.g. 
prolonged release of perfumes. Incorporation of 
cosmetic compounds and modulation of release is even 
more flexible when using NLC. In addition, the release 
of insect repellents has been described [70,71]. A 
feature of general interest is the stabilisation of 
chemically labile compounds. The solid matrix of the 
lipid nanoparticle protects them against chemical 
degradation, e.g. Retinol[72] and coenzyme Q10. A 
recently discovered feature is the sunscreen blocking 
effect of lipid nanoparticles. Similar to particles such as 
titanium dioxide the crystalline lipid particles scatter 
UV light, thus protecting against UV irradiation. In 
addition, it was found that incorporation of sunscreens 
leads to a synergistic UV blocking effect of the 
particulate blocker lipid nanoparticle and the molecular 
blocker. In vitro, crystalline lipid nanoparticles with the 
same sunscreen concentration exhibited twice the UV 
protection effect compared with an O/W emulsion 
loaded with the sunscreen.  
 
Physicochemical characterization ofNLCs 
The physicochemical characterization for NLCs is 
essentialto confirm quality control and stability. Both 
physicaland chemical properties can be determined for 
NLCs.Microscopic and Macroscopic techniques are 
used in development of colloidal system84. Various 
techniques like particle size analysis, zeta‐potential, 
transmission electron microscopy, differential scanning 
calorimetry (DSC), X‐ Ray scattering, polarized light 
microscopy, laser diffraction (LD), field‐flow 
fractionation (FFF) were performed to investigate the 
structure, mobility and molecular environment of the 
compounds. These techniques also reveal the physical 
and chemical stability of formulation, surface 
chargetend to determine the particles will flocculate or 
not. 
 
Particle Size 
The particle size is important parameter in process 
control and quality assurance because physical stability 
of vesicle dispersion depends on particle size andas 
particle size decreases, surface area characteristics 
increases as a function of total volume, photon 
correlation spectroscopy (PCS) based on laser light 
diffraction provides an appropriate method for 
investigation and can be applied for particles ranging 
below 200 nm and up to 1µm 86. For particles below 
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200nm Rayleigh’s theory holds that the scattering 
intensity tobe proportional to the sixth potency of the 
particle diameter. Both, Fraunhofer’s and Rayleigh’s 
theories, are only approximations of Mie’s theory 
which claims that the scattering intensity depends on 
the scattering angle, theabsorption and the size of the 
particles as well as therefractive indices of both the 
particles and the dispersion medium. 
 
Zeta potential (ZP) 
 
Zeta potential is the electric potential of a particle in a 
suspension. It is a parameter which is very useful for 
the assessment of the physical stability of colloidal 
dispersions. In suspensions the surfaces of particles 
develop a charge due to ionization of surface groups or 
adsorption of ions. This charge depends on both the 
surface chemistry of the particles and the media around 
these particles. The surface charge generates a potential 
around the particle, which is at the highest near the 
surface and decays with distance into the medium. The 
zeta potential can be measured by determining the 
velocity of the particles in an electrical field 
(electrophoresis measurement). 
 
Scanning electron microscopy (SEM) 
This technique can be used to investigate the shape of 
the particles prepared and to assess the particle size of 
these particles. Aqueous NLC dispersions can be 
applied and spread on a sample holder (thin carbon 
film). The samples will be placed inside of the vacuum 
column of the microscope and the air was pumped out 
of the chamber. An electron gun placed at the top of 
the column emits a beam of high energy primary 
electrons. The beam of the electrons passes through the 
lenses which concentrates the electrons to a fine spot 
and scan across the specimen row by row. As the 
focused electron beam hits a spot on the sample, 
secondary electrons are emitted by the specimen 
through ionization. A detector counts these secondary 
electrons. The electrons are collected by a laterally 
placed collector and these signals are sent to an 
amplifier. 
 
Differential scanning calorimetry (DSC) 
DSC is usually used to get information about both the 
physical and the energetic properties of a compound or 
formulation. DSC measures the heat loss or gain as a 
result of physical or chemical changes within a sample 
as a function of the temperature. DSC and powder is 
performed for the determination of the degree of 
crystallinity of the particle dispersion. The rate of 
crystallinity using DSC is estimated by comparison of 
the melting enthalpy/g of the bulk material with the 
melting enthalpy/g of the dispersion. 
Nuclear magnetic resonance (NMR)  
NMR can be used to determine both the size and the 
qualitative nature of nanoparticles. The selectivity 
afforded by chemical shift complements the sensitivity 
to molecular mobility to provide information on the 
physicochemical status of components within the 
nanoparticle. Nuclear Magnetic Resonance (NMR). 
The mobility of the solid and liquid lipids is related to 
the width at half amplitude of the signals [73]. Broad 
signals and small amplitudes are characteristics of 
molecules with restricted mobility and strong 
interactions. The higher line width of NLCs compared 
to the physical mixture of the materials added in NLCs 
indicates the interaction of liquid oil with the solid 
lipid. Immobilization of the nanoparticles of NLCs is 
stronger compared to SLNs with totally crystallized 
cores. 
 
Atomic Force Microscopy (AFM) 
AFM is optimal for measuring morphological and 
surface features that are extremely small. AFM does 
not use photonsor electrons but a very small sharp-
tipped probe located at the free end of a cantilever 
driven by interatomic repulsive or attractive forces 
between the tip and surface of the specimen[74]. 
Although electron microscopy is still frequently used, 
the AFM technique offers substantial benefits: real 
quantitativedata acquisition in three dimensions, 
minimal sample preparation times, flexibility in 
ambient operating conditions, and effective 
magnifications at the  
nano levels [75]. 
 
X-ray Scattering 
With X-ray scattering experiments characteristic 
interferences the generated from an ordered 
microstucture. A typical interference pattern arises due 
to specific repeat distances of the associated interlayer 
spacing‘d’.According to Bragg’s equation ‘d’ can be 
calculated  
d= n/λ 2 sin θ 
Where, λ is the wavelength of the X- ray being used, n 
is an integer and nominates the order of the 
interference and θ is the angle under which the 
interference occurs. 
 
Transmission Electron Microscopy 
It is a technique where colloidal samples could be 
visualized at high resolution. Sufficient contrast can be 
given to a thin film of the frozen sample by use of 
osmium tetra- oxide. This allows the sample to be 
viewed directly in the TEM (at temperature -196º 
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C).The adjustment of the temperature to -196º C leads 
to a very poor pressure, so that the examination of the 
sample is possible by preservation of microstructure 
despite the high vacuum.  
 
Drug Release 
The controlled or sustained release of the drugs from 
NLCs can result in the prolonged half-life and retarded 
enzymatic attack in systematic circulation. The drug 
release behavior from NLCs is dependent upon the 
production temperature, emulsifier composition, and 
oil percentage incorporated in the lipid matrix [76]. 
The drug amount in the outer shell of the nanoparticles 
and on the particulate surface is released in a burst 
manner, while the drug incorporated into the 
particulate core is released in a prolonged way. 
Sustained release of the drugs can be explained 
considering both drug partitioning between the lipid 
matrix and water, as well as the barrier function of the 
interfacial membrane [77,78]. The dialysis method and 
the utilization of the Franz cell are the modes for 
measuring in vitro drug release from nanoparticles. The 
interpretation of in vitro drug release profiles should 
consider the specific environment in the in vivo status. 
Enzymatic degradation of lipid nanoparticles may be 
influenced to a relevant extent by the composition of 
the particles. 
 
Factors affecting the Drug release 
 The release study must be performed to compare the 
capacity of different samples to retain the drug 
incorporated for a longer time and release it slowly 
from the lipid matrix of the nanoparticles. Many factors 
that could affect the release profile of the drug from the 
NLC system. The effect of the particle size, the lipid 
matrix, the surfactant, the drug concentration in the 
lipid matrix and the drug type can be studied. 
Particle size  
The particle size of a colloidal system (e.g. NLC) is a 
crucial factor for the release of the material(s) 
incorporated inside the particles. 
Lipid matrix 
 Different lipid matrices lead to different release 
profiles. The lipids have different crystals order and 
crystallization modification, different melting points 
and different hydrophilic lipophilic balance (HLB) 
values, e.g. Apifil HLB = 9.4, Compritol 888 HLB = 2. 
This makes the affinity of the drug to be entrapped 
within the lipid matrix different from one lipid to 
another. 
 
Surfactant 
Surfactants as they are used to stabilize the particles in 
the dispersion media (or emulsify the oil in water) may 
affect the structure of the lipid nanoparticles. This 
happens because of the interaction between the 
emulsifying agent molecules and the lipid molecules. 
Depending on the HLB of the surfactant and the 
molecular weight of the surfactant molecules, the 
affinity of the surfactant to the lipid differs. Having the 
surfactant molecules embedded in the lipid matrix 
might dramatically affect the crystallization of the 
lipid, and leave spaces in the lipid lattice. These spaces 
will give rise to higher loading capacity of drug, 
incorporation in imperfections inside the particle 
matrix and eventually a slower release profile. 
Moreover, the ability of the surfactant to stabilize the 
oil droplets (in the lipid melted state during 
homogenization) and form smaller NLCs gives the 
surfactant also a role through the size of the formed 
lipid particles. The physicochemical properties of the 
NLCs are essentially influenced by the type of 
surfactant used. 
 
Drug loading 
 Drug loading might affect the release profile. It 
depends on the affinity of the drug to mix with the lipid 
and be enclosed in the matrix. 
 
Drug type 
The drug type affects the release profile because with 
the different compositions of drugs there are different 
affinities to the lipid matrix.Nanostructured lipid 
carriers have unique characteristics that can enhance 
the performance of a variety of incorporated drug 
forms. 
 
Conclusion 
In the20th century, Paul Ehrlich envisioned his magic 
bullet concept; the idea that drugs reach the right site in 
the body, at the right time, at right concentration. The 
aim has been to developed therapeutic nanotechnology 
undertaking, particularly for targetted drug therapy The 
smart NLCs as the new generation offer much more 
flexibility in drug loading, modulation of release and 
improved performance in producing final dosage forms 
such as creams, tablets, capsules and injectables. The 
effort to develop alternative routes and to treat other 
diseases with NLCs should be continued to extend their 
applications. Permeation via the gastrointestinal tract 
and BBB may be a future trend. The combination of 
two therapeutically active agents to be included in a 
single nanosystem is another consideration for future 
development. 
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